Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangniaole Tablets (糖尿乐片) is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Hefei Huafang Pharmaceutical Technology for the treatment of diabetes mellitus. The drug is primarily indicated for "Xiao Ke" syndrome (wasting and thirsting disorder), which corresponds to Type 2 diabetes in Western medicine. The formulation is composed of multiple botanical extracts, typically including *Astragalus membranaceus*, *Rehmannia glutinosa*, and *Trichosanthes kirilowii*, which work synergistically to nourish Yin, supplement Qi, and clear heat. Clinically, it is used to regulate blood glucose levels and alleviate common diabetic symptoms such as polydipsia, polyphagia, and polyuria. The product is approved in China and is administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tangniaole tablets.